This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Psychiatry  • Depression  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Dr Wagner and colleagues¹ stated that the "significance of the results is clinically as well as statistically relevant," an assertion that reaches well beyond the trial's results. The average improvement in the main outcome measure—the CDRS-R—was 22.84 points for the sertraline group vs 20.19 points for the placebo group. The authors did not report the standard deviation, however; thus, an effect size cannot be calculated. However, simple division shows that the gains made by the placebo group were 88.4% of those in the active medication group, leaving the active medication superior by less than a 12% margin compared with an inert placebo. The slight difference between active and inactive treatment in the main outcome measure, while statistically significant, is of questionable clinical relevance. Statistically significant differences were also found on the Clinical Global Impression (CGI) Improvement and Severity of Illness scales. While these scales are popular in . . . [Full Text of this Article]

Glen I. Spielmans, MS
Department of Psychiatry
Indiana University School of Medicine
Indianapolis

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Efficacy of Sertraline in the Treatment of Children and Adolescents With Major Depressive Disorder
Maju Mathews, Manu Mathews, and Joanne Mathews
JAMA. 2004;291(1):40.
EXTRACT | FULL TEXT  

Efficacy of Sertraline in the Treatment of Children and Adolescents With Major Depressive Disorder
David Price
JAMA. 2004;291(1):40-41.
EXTRACT | FULL TEXT  

Efficacy of Sertraline in the Treatment of Children and Adolescents With Major Depressive Disorder
Antal E. Solyom
JAMA. 2004;291(1):41-42.
EXTRACT | FULL TEXT  

Efficacy of Sertraline in the Treatment of Children and Adolescents With Major Depressive Disorder—Reply
Karen D. Wagner, Christopher J. Wohlberg, and Ruoyong Yang
JAMA. 2004;291(1):42.
EXTRACT | FULL TEXT  

Efficacy of Sertraline in the Treatment of Children and Adolescents With Major Depressive Disorder: Two Randomized Controlled Trials
Karen Dineen Wagner, Paul Ambrosini, Moira Rynn, Christopher Wohlberg, Ruoyong Yang, Michael S. Greenbaum, Ann Childress, Craig Donnelly, and Deborah Deas
JAMA. 2003;290(8):1033-1041.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sertraline and Depression in Children
Garland
JAMA 2004;291:1561-1561.
FULL TEXT